STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

3M Owns 25.57M Solventum Shares; Proxy Limits Voting Power

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

3M Company reported ownership of 25,569,190 shares of Solventum Corporation common stock, representing approximately 14.75% of the outstanding shares based on 173,387,798 shares outstanding as of July 31, 2025. The filing states that 3M granted Solventum a proxy under a Stockholder and Registration Rights Agreement dated March 31, 2024, so 3M does not exercise voting power over these shares and therefore reports 0 votes while retaining sole dispositive power to sell or direct disposition of the shares.

The Schedule 13G/A was signed on behalf of 3M Company by Kevin H. Rhodes, Executive Vice President, Chief Legal Affairs Officer & Secretary, dated August 18, 2025. The percentage is calculated from Solventum’s August 8, 2025 SEC filing reporting outstanding shares as of July 31, 2025.

Positive

  • Material economic stake: 3M beneficially owns 25,569,190 shares (~14.75%), a meaningful ownership position.
  • Sole dispositive power: 3M retains the ability to sell or direct disposition of the full share block.
  • Clear disclosure: Filing cites the Stockholder and Registration Rights Agreement and quantifies shares and percentage based on outstanding shares.

Negative

  • No voting power: 3M reports 0 shares with sole or shared voting power due to the proxy arrangement.
  • Potential governance limitation: Despite economic exposure, 3M cannot unilaterally influence corporate votes through this stake.

Insights

TL;DR: 3M retains a sizable economic stake in Solventum (14.75%) but has no voting power due to a proxy arrangement.

3M’s 25.57 million-share position is material relative to the 173.39 million shares outstanding, representing nearly 15% ownership. That level of ownership is large enough to influence valuation perceptions and secondary-market liquidity for Solventum shares. However, because 3M has granted a proxy to vote in proportion to other stockholders, its economic exposure is not matched by independent voting control, reducing its direct governance influence. For investors, the key takeaway is a meaningful economic stake without unilateral voting authority.

TL;DR: The proxy-based voting arrangement limits 3M’s governance control despite a substantial ownership stake.

The Stockholder and Registration Rights Agreement dated March 31, 2024, and the proxy described in this filing indicate a deliberate separation of economic ownership from voting control. This arrangement can reassure Solventum’s independent governance by preventing a large shareholder from exercising block voting while still allowing 3M to monetize or transfer its economic interest. Materially, the filing clarifies that all voting power is exercised proportionally, which reduces the likelihood of a control contest arising solely from 3M’s stake.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



3M Company
Signature:3M Company
Name/Title:Kevin H. Rhodes, Executive Vice President, Chief Legal Affairs Officer & Secretary
Date:08/18/2025

FAQ

How many Solventum (SOLV) shares does 3M own?

3M Company beneficially owns 25,569,190 shares of Solventum common stock according to this Schedule 13G/A.

What percentage of Solventum does 3M own?

The filing states approximately 14.75% based on 173,387,798 shares outstanding as of July 31, 2025.

Does 3M have voting control over its Solventum shares?

No. 3M reports 0 sole voting power and 0 shared voting power because it granted a proxy to Solventum under a March 31, 2024 agreement.

Can 3M sell the Solventum shares it owns?

Yes. The filing reports sole dispositive power over all 25,569,190 shares, indicating 3M can dispose of the shares.

When was this Schedule 13G/A signed?

The signature on the filing is dated August 18, 2025, signed by Kevin H. Rhodes for 3M Company.
Solventum Corporation

NYSE:SOLV

SOLV Rankings

SOLV Latest News

SOLV Latest SEC Filings

SOLV Stock Data

14.79B
147.58M
14.9%
66.72%
2.46%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
ST. PAUL